Atria Investments LLC acquired a new stake in Laboratory Corporation of America Holdings (NYSE:LH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,805 shares of the medical research company’s stock, valued at approximately $278,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in Laboratory Corporation of America Holdings during the fourth quarter valued at approximately $360,000. Baltimore Washington Financial Advisors Inc. raised its position in Laboratory Corporation of America Holdings by 1.1% in the fourth quarter. Baltimore Washington Financial Advisors Inc. now owns 38,335 shares of the medical research company’s stock valued at $4,921,000 after buying an additional 415 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in Laboratory Corporation of America Holdings by 3.0% in the fourth quarter. UBS Asset Management Americas Inc. now owns 890,141 shares of the medical research company’s stock valued at $114,277,000 after buying an additional 25,775 shares during the last quarter. Hudson Bay Capital Management LP raised its position in Laboratory Corporation of America Holdings by 580.8% in the fourth quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the medical research company’s stock valued at $9,629,000 after buying an additional 90,600 shares during the last quarter. Finally, Kentucky Retirement Systems purchased a new position in Laboratory Corporation of America Holdings during the fourth quarter valued at approximately $960,000. 91.09% of the stock is owned by institutional investors.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 153.30 on Monday. Laboratory Corporation of America Holdings has a 12-month low of $119.51 and a 12-month high of $154.82. The company has a 50 day moving average price of $142.43 and a 200 day moving average price of $138.87. The company has a market capitalization of $15.68 billion, a P/E ratio of 21.06 and a beta of 0.93.

Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings results on Tuesday, April 25th. The medical research company reported $2.22 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.03. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Laboratory Corporation of America Holdings had a return on equity of 16.99% and a net margin of 7.76%. The company’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.02 EPS. Equities analysts anticipate that Laboratory Corporation of America Holdings will post $9.43 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/atria-investments-llc-invests-278000-in-laboratory-corporation-of-america-holdings-lh/1444620.html.

Several research analysts have commented on LH shares. Zacks Investment Research lowered shares of Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Jefferies Group LLC dropped their price objective on shares of Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating for the company in a research note on Friday, April 28th. Credit Suisse Group reaffirmed a “buy” rating and set a $146.00 price objective on shares of Laboratory Corporation of America Holdings in a research note on Sunday, May 28th. ValuEngine downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Saturday, June 3rd. Finally, BidaskClub downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $154.35.

In related news, SVP Lance Berberian sold 3,613 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $139.84, for a total transaction of $505,241.92. Following the completion of the transaction, the senior vice president now directly owns 5,789 shares in the company, valued at approximately $809,533.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean-Luc Belingard sold 992 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $142.19, for a total value of $141,052.48. Following the transaction, the director now owns 32,935 shares of the company’s stock, valued at $4,683,027.65. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.